loading page

Clinical Characteristics of SARS-COV-2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi-Center Retrospective Study
  • +14
  • Lin Wang,
  • Ruihua Mi,
  • Lin Chen,
  • Jia Liu,
  • Haiping Yang,
  • Meng Hu,
  • Zhao Xiaoqiang,
  • Yan Zhang,
  • Xiaobing Xu,
  • Bing Liu,
  • Hongmian Zhao,
  • Li Qianyu,
  • Tao Liu,
  • Chen Zhenzhu,
  • Jinxiao Yao,
  • Ying Yang,
  • Xudong Wei
Lin Wang
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Author Profile
Ruihua Mi
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Author Profile
Lin Chen
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Author Profile
Jia Liu
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Author Profile
Haiping Yang
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Meng Hu
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Zhao Xiaoqiang
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Yan Zhang
Anyang District Hospital
Author Profile
Xiaobing Xu
Anyang District Hospital
Author Profile
Bing Liu
Pingdingshan First People Hospital
Author Profile
Hongmian Zhao
Huaihe Hospital of Henan University
Author Profile
Li Qianyu
Huaihe Hospital of Henan University
Author Profile
Tao Liu
Zhoukou Central Hospital
Author Profile
Chen Zhenzhu
Zhoukou Central Hospital
Author Profile
Jinxiao Yao
Nanyang Second Peoples Hospital
Author Profile
Ying Yang
Nanyang Second Peoples Hospital
Author Profile
Xudong Wei
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University

Corresponding Author:[email protected]

Author Profile

Abstract

The purpose is to analyze the clinical features and mortality rates of Chinese acute leukemia patients affected by COVID-19 infection. We retrospectively analyzed the clinical characteristics of acute leukemia patients with COVID-19 infection in Henan Province, China, from December 1, 2022, to January 31, 2023. Our study included 100 cases of acute leukemia with COVID-19 infection. The median age was 49.5 years old (58% male and 42% female). Patients with acute myeloid leukemia were 76%, and 24% were acute lymphoblastic leukemia.86% of patients were asymptomatic; 35% of patients received antibiotic treatment, and 25% received antiviral treatment. For the first time, we analyzed the factors affecting the days of nucleic acid cycle threshold (CT) (CT≤36) in acute leukemia patients infected with COVID-19; the days in severe cases and dead patients was significantly longer. We found that in patients with neutropenia who were receiving antibiotic treatment the days was significantly longer, whereas in patients receiving antiviral treatment or delayed treatment this number was shorter. All patients were followed up for three months, and the overall mortality rate was 6%. Although multivariate analysis showed that no death related factor, univariate analysis showed that neutropenia was the main factor affecting mortality in patients infected with COVID-19. Early application of antiviral drug shorten the number of days of COVID-19 nucleic acid CT value≤36 in AL patients infected with COVID-19, which may further reduce the proportion of patients with severe symptoms or death.
29 Mar 2024Reviewer(s) Assigned
07 May 2024Review(s) Completed, Editorial Evaluation Pending
18 Jul 20241st Revision Received
07 Aug 2024Assigned to Editor
07 Aug 2024Submission Checks Completed
07 Aug 2024Review(s) Completed, Editorial Evaluation Pending
07 Aug 2024Reviewer(s) Assigned